Metabolomic biomarkers for the detection of obesity-driven endometrial cancer
Campbell, A. E.
MacKintosh, M. L.
Derbyshire, A. E.
Kitson, S. J.
Sivalingam, V. N.
Whetton, Anthony D
Crosbie, E. J.
AffiliationDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, 5th Floor Research, St Mary's Hospital, Oxford Road, Manchester M13 9W
MetadataShow full item record
AbstractEndometrial cancer is the most common malignancy of the female genital tract and a major cause of morbidity and mortality in women. Early detection is key to ensuring good outcomes but a lack of minimally invasive screening tools is a significant barrier. Most endometrial cancers are obesity-driven and develop in the context of severe metabolomic dysfunction. Blood-derived metabolites may therefore provide clinically relevant biomarkers for endometrial cancer detection. In this study, we analysed plasma samples of women with body mass index (BMI) ≥30kg/m2 and endometrioid endometrial cancer (cases, n = 67) or histologically normal endometrium (controls, n = 69), using a mass spectrometry-based metabolomics approach. Eighty percent of the samples were randomly selected to serve as a training set and the remaining 20% were used to qualify test performance. Robust predictive models (AUC > 0.9) for endometrial cancer detection based on artificial intelligence algorithms were developed and validated. Phospholipids were of significance as biomarkers of endometrial cancer, with sphingolipids (sphingomyelins) discriminatory in post-menopausal women. An algorithm combining the top ten performing metabolites showed 92.6% prediction accuracy (AUC of 0.95) for endometrial cancer detection. These results suggest that a simple blood test could enable the early detection of endometrial cancer and provide the basis for a minimally invasive screening tool for women with a BMI ≥ 30 kg/m2.
CitationNjoku K, Campbell AE, Geary B, MacKintosh ML, Derbyshire AE, Kitson SJ, et al. Metabolomic Biomarkers for the Detection of Obesity-Driven Endometrial Cancer. Cancers (Basel). 2021;13(4).
- Metabolomic prediction of endometrial cancer.
- Authors: Bahado-Singh RO, Lugade A, Field J, Al-Wahab Z, Han B, Mandal R, Bjorndahl TC, Turkoglu O, Graham SF, Wishart D, Odunsi K
- Issue date: 2017 Dec 1
- Identification of novel diagnostic biomarkers in endometrial cancer using targeted metabolomic profiling.
- Authors: Kozar N, Kruusmaa K, Dovnik A, Bitenc M, Argamasilla R, Adsuar A, Goswami N, Takač I, Arko D
- Issue date: 2020 Dec 24
- Metabolomic biomarkers in cervicovaginal fluid for detecting endometrial cancer through nuclear magnetic resonance spectroscopy.
- Authors: Cheng SC, Chen K, Chiu CY, Lu KY, Lu HY, Chiang MH, Tsai CK, Lo CJ, Cheng ML, Chang TC, Lin G
- Issue date: 2019 Oct 29
- Validation of ultrasound strategies to assess tumor extension and to predict high-risk endometrial cancer in women from the prospective IETA (International Endometrial Tumor Analysis)-4 cohort.
- Authors: Verbakel JY, Mascilini F, Wynants L, Fischerova D, Testa AC, Franchi D, Frühauf F, Cibula D, Lindqvist PG, Fruscio R, Haak LA, Opolskiene G, Alcazar JL, Mais V, Carlson JW, Sladkevicius P, Timmerman D, Valentin L, Bosch TVD, Epstein E
- Issue date: 2020 Jan
- Metabolomic Signature of Endometrial Cancer.
- Authors: Troisi J, Sarno L, Landolfi A, Scala G, Martinelli P, Venturella R, Di Cello A, Zullo F, Guida M
- Issue date: 2018 Feb 2